Approval · Notice of Compliance 29128 · 2022
TWYNSTA: Notice of Compliance 29128
Issued October 4, 2022
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 29128
- Date
- October 4, 2022
- Company
- Boehringer Ingelheim (Canada) Ltd.Burlington, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Safety Update to the Product Monograph (PM) and migrate the PM to the 2020 Master Template.
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| TWYNSTA | Not yet assigned | — |
Medicinal ingredients
- AMLODIPINE BESYLATE 5 MG per TAB
- TELMISARTAN 40 MG per TAB
- AMLODIPINE BESYLATE 10 MG per TAB
- TELMISARTAN 80 MG per TAB